Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Morgan Stanley — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Morgan Stanley trades at $181.3 (market cap $293.13B). The key difference: Morgan Stanley is far larger — about 9.4× GE HealthCare Technologies Inc. Common Stock's market cap, and Morgan Stanley pays the higher dividend (2.46%). Which is the better fit depends on your goals.
| GEHC | MS | |
|---|---|---|
Market Cap | $31.07B | $293.13B |
Volume | 3,443,020 | 8,184,975 |
Sector | Health | Financials |
52-Week High | $88.16 | $228.42 |
52-Week Low | $59.48 | $154.37 |
Enterprise Value | $39.53B | $658.86B |
Dividend Yield | 0.23% | 2.46% |
Typical Hold Time | — | 90 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Morgan Stanley (MS) trades at $190.02, showing stability with no recent price change. The stock exhibits a bearish technical signal but maintains strong fundamentals, with revenue growing to $66.0B in 2025 and net income reaching $16.9B. Recent earnings have consistently beaten expectations, and analyst consensus remains bullish with a $229.25 price target. The company highlights growth in wealth management and AI financing as key drivers.
The outlook for MS is positive, supported by earnings momentum and strategic growth areas, though risks include volatile cash flows and high debt levels. Investment opportunity lies in its above-sector profitability and analyst upside, but investors should monitor macroeconomic sensitivity and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
